Clinical Trials Logo
  1. Home
  2. Herpes Genitalis
  3. NCT02837575

Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine — HSV-2  

Herpes Genitalis Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection

Clinical Trial Summary

The purpose of this trial is to evaluate the safety and efficacy of a therapeutic DNA vaccine in adults with symptomatic herpes simplex virus type 2 (i.e., genital herpes).

Clinical Trial Description

To evaluate the safety and efficacy of 4 doses of VCL-HB01, a therapeutic HSV plasmid DNA vaccine formulated with Vaxfectin® in HSV-2-seropositive adults with a reported history of symptomatic genital herpes for at least one year. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02837575
Study type Interventional
Source Vical
Contact
Status Completed
Phase Phase 2
Start date September 2016
Completion date December 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT02852876 - Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food Phase 1
Completed NCT04664127 - Study of the Efficacy and Safety of Combined Treatment of Patients With Severe Herpes Simplex (HSV) Infection by Valacyclovir and Interferon Inducer Kagocel
Completed NCT00405821 - Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda Phase 2
Completed NCT04165122 - Monoclonal Antibody Therapy Against Chronic Herpes Simplex Virus 2 Infection Phase 2
Completed NCT00158483 - Anti-Herpetic Treatment of Genital Ulcer : Effect on HIV & Herpes Shedding (ANRS 1212) Phase 2
Terminated NCT00079911 - A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons Phase 4
Active, not recruiting NCT04950712 - An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.
Completed NCT00486200 - A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes Phase 2
Completed NCT00158860 - A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies. Phase 4
Active, not recruiting NCT00005663 - A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients Phase 3
Active, not recruiting NCT04073082 - Safety and Efficacy of Laser Therapy in Gynaecology
Terminated NCT00122525 - Effect of Male Circumcision on HIV Incidence (ANRS 1265) Phase 3
Completed NCT00158509 - Randomised Controlled Trial Assessing the Impact of Genital Herpes Suppressive Therapy on HIV Shedding Phase 2
Completed NCT00076232 - A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes Phase 3
Completed NCT00023582 - HIV and Genital Herpes Among High-Risk Men Who Have Sex With Men (MSM) in Lima, Peru N/A